Especially SDHB-mutation carriers have higher risk of developing a metastatic disease and shorter survival than patients with a malignant PPGL, but without SDHB mutations (Benn et al., 2015; Nazar et al., 2019; Gimenez-Roqueplo et al., 2003; King et al., 2011; Brouwers et al., 2006; Turkova et al., 2016; Hamidi et al., 2017). Here, SDHB is linked to metastatic neoplasm.